Son Guk Jin, CEO; Paula Mendoza, CEOIn 2019, AnaPath Services demonstrated its unwavering commitment to research excellence by launching AnaPath Group. This significant milestone was achieved through the strategic acquisition of AnaPath Research, which brought together the Spanish In vivo site of RCC/Harlan Laboratories/Envigo under one integrated entity. This merger not only strengthened AnaPath’s portfolio but also solidified its position as a premier global CRO. Despite subsequent changes in nomenclature and organizational adjustments, AnaPath Group remains steadfast in its dedication to providing top-notch services.
“Our stature as a smaller entity compared to industry giants grants us the agility to provide tailored services that align with client expectations,” says Paula Mendoza, CEO of AnaPath Spain.
The CRO personalises its services by identifying specific attributes, such as quality or safety that set the drug apart from available market alternatives.
“During drug safety evaluations, unexpected results may occur by mis-leaded strategies. We have transparent discussions with clients and collaborate with them on how to make the R&D project a success,” says Son Guk Jin, CEO of AnaPath Korea.
The firm’s commitment to guiding clients through their entire R&D workflow has nurtured deep loyalty and enduring relationships. A case study best illustrates this fact. AnaPath once collaborated with a university-affiliated local company to develop a new compound and offered pre-clinical trial packages, proprietary bio-analytics, in-vivo studies and pathology evaluation. This support facilitated the client’s successful passage through pre-clinical trials. Satisfied with the service, the company returned seeking guidance in clinical trials. Although not a primary service, AnaPath supports them in the crucial R&D phase. It also retains valuable compound information in its repository, which contains a pool of amassed molecule data previously collected from its clientele. This wealth of data empowers the firm with unmatched R&D capability in the industry.
Our stature as a smaller entity compared to industry giants grants us the agility to provide tailored services aligning with client expectations.
AnaPath’s peerless reputation in the field is further bolstered by its workforce, with 80 percent originating from Harlan. These experts are led by Dr. Klaus Weber PhD, DVM, MSc. Biol, DJSTP, the firm’s founder and well-renowned toxicologic pathologist, who has previously collaborated with the FDA, MFDS (Korea), PMDA(Japan) and EMA, among other authorities. Their collective knowledge facilitates seamless adaptation to industry changes, including the transition to sector-wide standards for animal testing. AnaPath currently offers testing services across various animal species while supporting biologics in non-human primate projects, all conducted under GLP standards. In addition, the CRO has increased its investments in oligonucleotides, enabling the development of regulatory-compliant qPCR methods to facilitate bio-distribution studies, as an example.
The firm’s branches in Spain and Basel specialise in biological research and developing new chemical entities, respectively, enabling it to operate efficiently in each field. Each division employs highly qualified scientists who have worked with the company for years due to its robust internal human resources policy. This cultivated loyalty enabled them to foster long-term client relationships by offering strong scientific support and customised services. Equipped with these strengths, AnaPath is on a mission to be the global leader in the CRO industry within the next five years.
